These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27974464)

  • 1. Affinity Maturation of a Cyclic Peptide Handle for Therapeutic Antibodies Using Deep Mutational Scanning.
    van Rosmalen M; Janssen BM; Hendrikse NM; van der Linden AJ; Pieters PA; Wanders D; de Greef TF; Merkx M
    J Biol Chem; 2017 Jan; 292(4):1477-1489. PubMed ID: 27974464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.
    Donaldson JM; Zer C; Avery KN; Bzymek KP; Horne DA; Williams JC
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17456-61. PubMed ID: 24101516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meditope-Fab interaction: threading the hole.
    Bzymek KP; Ma Y; Avery KN; Horne DA; Williams JC
    Acta Crystallogr F Struct Biol Commun; 2017 Dec; 73(Pt 12):688-694. PubMed ID: 29199990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope.
    Makabe K; Yokoyama T; Uehara S; Uchikubo-Kamo T; Shirouzu M; Kimura K; Tsumoto K; Asano R; Tanaka Y; Kumagai I
    Sci Rep; 2021 Mar; 11(1):5790. PubMed ID: 33707468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.
    Voigt M; Braig F; Göthel M; Schulte A; Lamszus K; Bokemeyer C; Binder M
    Neoplasia; 2012 Nov; 14(11):1023-31. PubMed ID: 23226096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclization strategies of meditopes: affinity and diffraction studies of meditope-Fab complexes.
    Bzymek KP; Ma Y; Avery KA; Horne DA; Williams JC
    Acta Crystallogr F Struct Biol Commun; 2016 Jun; 72(Pt 6):434-42. PubMed ID: 27303895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling.
    Boersma YL; Chao G; Steiner D; Wittrup KD; Plückthun A
    J Biol Chem; 2011 Dec; 286(48):41273-41285. PubMed ID: 21979953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of somatic mutations on EGFR interaction with anti-EGFR monoclonal antibodies: Implication for acquired resistance.
    Tabasinezhad M; Omidinia E; Talebkhan Y; Omrani MD; Mahboudi F; Ghaedi H; Wenzel W
    Proteins; 2020 Jan; 88(1):3-14. PubMed ID: 31228284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterial production and structure-functional validation of a recombinant antigen-binding fragment (Fab) of an anti-cancer therapeutic antibody targeting epidermal growth factor receptor.
    Kim JH; Sim DW; Park D; Jung TG; Lee S; Oh T; Ha JR; Seok SH; Seo MD; Kang HC; Kim YP; Won HS
    Appl Microbiol Biotechnol; 2016 Dec; 100(24):10521-10529. PubMed ID: 27470143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deep Mutational Scans as a Guide to Engineering High Affinity T Cell Receptor Interactions with Peptide-bound Major Histocompatibility Complex.
    Harris DT; Wang N; Riley TP; Anderson SD; Singh NK; Procko E; Baker BM; Kranz DM
    J Biol Chem; 2016 Nov; 291(47):24566-24578. PubMed ID: 27681597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
    Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
    J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
    Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
    J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep mutational scanning of an antibody against epidermal growth factor receptor using mammalian cell display and massively parallel pyrosequencing.
    Forsyth CM; Juan V; Akamatsu Y; DuBridge RB; Doan M; Ivanov AV; Ma Z; Polakoff D; Razo J; Wilson K; Powers DB
    MAbs; 2013; 5(4):523-32. PubMed ID: 23765106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands.
    Jin P; Zhang J; Beryt M; Turin L; Brdlik C; Feng Y; Bai X; Liu J; Jorgensen B; Shepard HM
    Mol Med; 2009; 15(1-2):11-20. PubMed ID: 19048033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response.
    Hartmann C; Müller N; Blaukat A; Koch J; Benhar I; Wels WS
    Oncogene; 2010 Aug; 29(32):4517-27. PubMed ID: 20514015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering a high-affinity peptide binding site into the anti-CEA mAb M5A.
    Zer C; Avery KN; Meyer K; Goodstein L; Bzymek KP; Singh G; Williams JC
    Protein Eng Des Sel; 2017 Jun; 30(6):409-417. PubMed ID: 28431161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer.
    Nair S; Trummell HQ; Rajbhandari R; Thudi NK; Nozell SE; Warram JM; Willey CD; Yang ES; Placzek WJ; Bonner JA; Bredel M
    PLoS One; 2020; 15(2):e0229077. PubMed ID: 32069320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.
    Garrido G; Tikhomirov IA; Rabasa A; Yang E; Gracia E; Iznaga N; Fernández LE; Crombet T; Kerbel RS; Pérez R
    Cancer Biol Ther; 2011 Feb; 11(4):373-82. PubMed ID: 21150278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
    Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
    BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.